@brooklynstlaurent's GLP-1 investment advice, fact-checked

What did @brooklynstlaurent actually say?

Honestly? Not much, medically speaking. The creator said, "Everything's adding up, you've been through hell and bad, that's why you're bad as fuck and you know you are." That's it. There are no clinical claims here, no dosing advice, no promises about weight loss results. This is a motivational caption set against what the platform categorizes as GLP-1 content. The video's medical footprint is essentially zero.

The caption, "you sign to invest in yourself," does the heavier lifting in terms of framing GLP-1 treatment as a self-improvement decision. That framing is worth examining, even if the spoken words are pure affirmation. Context matters on TikTok, where a 3.4 million view count means this video is shaping how a lot of people think about starting weight-loss medication, whether or not the creator intended that.

Does the science back this up?

There is nothing in the transcript to fact-check in a traditional clinical sense, so the real question is whether the broader "invest in yourself" framing around GLP-1 therapy is grounded in anything real. To a meaningful degree, it is, but with serious caveats.

GLP-1 receptor agonists like semaglutide and tirzepatide have strong trial data behind them. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide produced up to 22.5% mean body weight reduction over 72 weeks in people with obesity. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4 mg produced roughly 15% mean weight loss. These are not trivial numbers. For patients who qualify, the decision to start can be genuinely significant for metabolic health. But framing medication as purely a self-investment erases the medical complexity, side effect profiles, and access barriers that are very much part of this picture.

What did they get wrong (or right)?

Credit where it's due: the creator did not make a single false clinical claim. No one told viewers that semaglutide "cures" anything, no dose was mentioned, and no compounded product was falsely equated to a brand-name drug. In a GLP-1 content ecosystem filled with genuinely dangerous misinformation, that's not nothing.

What the video does wrong, or at least incompletely, is in its framing. "Invest in yourself" positions GLP-1 medication primarily as an aspirational lifestyle choice rather than a medical treatment with eligibility criteria, contraindications, and real discontinuation challenges. Research from Wilding et al. (2022, Diabetes, Obesity and Metabolism) found that patients regained roughly two-thirds of lost weight within a year of stopping semaglutide. That is not a detail that fits neatly into a motivational TikTok, but it is a detail that 3.4 million viewers arguably deserve to know.

What should you actually know?

GLP-1 therapy is not a personality trait, a self-care ritual, or a sign of personal commitment. It is a class of medications with real efficacy data, real side effects, real costs, and real gaps in long-term evidence. The motivational framing common in this content category is not inherently harmful, but it can set expectations that the drugs themselves cannot meet, and it can push people toward obtaining medications outside of clinical supervision.

If you are considering a GLP-1 agonist, the starting point is a conversation with a licensed provider who can assess your BMI, metabolic history, cardiovascular risk, and any contraindications like a personal or family history of medullary thyroid carcinoma, which is a labeled warning for this drug class per FDA prescribing information. Compounded semaglutide and tirzepatide exist in a separate regulatory category from FDA-approved branded versions. They are not the same product legally or clinically, and anyone telling you otherwise is either uninformed or not being straight with you.

• GLP-1 medications require ongoing use to maintain results in most patients
• Common side effects include nausea, vomiting, and gastrointestinal distress, particularly during dose escalation
• Access, cost, and insurance coverage remain significant barriers for many eligible patients
• A regulated telehealth evaluation is the appropriate first step, not a TikTok comment section